» Articles » PMID: 30637914

Tn Antigen Promotes Human Colorectal Cancer Metastasis Via H-Ras Mediated Epithelial-mesenchymal Transition Activation

Overview
Journal J Cell Mol Med
Date 2019 Jan 15
PMID 30637914
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Tn antigen is a truncated O-glycan, frequently detected in colorectal cancer (CRC), but its precise role in CRC metastasis is not well addressed. Here we investigated the effects of Core 1 β3Gal-T specific molecular chaperone (Cosmc) deletion-mediated Tn antigen exposure on CRC metastasis and its underlying mechanism. We first used CRISPR/Cas9 technology to knockout Cosmc, which is required for normal O-glycosylation, and thereby obtained Tn-positive CRC cells. We then investigated the biological consequences of Tn antigen expression in CRC. The results showed that Tn-positive cells exhibited an enhanced metastatic capability both in vitro and in vivo. A further analysis indicated that Tn antigen expression induced typical activation of epithelial-mesenchymal transition (EMT). Mechanistically, we found that H-Ras, which is known to drive EMT, was markedly up-regulated in Tn-positive cells, whereas knockdown of H-Ras suppressed Tn antigen induced activation of EMT. Furthermore, we confirmed that LS174T cells (Tn-positive) transfected with wild-type Cosmc, thus expressing no Tn antigen, had down-regulation of H-Ras expression and subsequent inhibition of EMT process. In addition, analysis of 438 samples in TCGA cohort demonstrated that Cosmc expression was reversely correlated with H-Ras, underscoring the significance of Tn antigen-H-Ras signalling in CRC patients. These data demonstrated that Cosmc deletion-mediated Tn antigen exposure promotes CRC metastasis, which is possibly mediated by H-Ras-induced EMT activation.

Citing Articles

Marine Lectins and Lectin-like Proteins as Promising Molecules Targeting Aberrant Glycosylation Signatures in Human Brain Tumors.

Buriak I, Kumeiko V Mar Drugs. 2024; 22(12).

PMID: 39728102 PMC: 11679326. DOI: 10.3390/md22120527.


Emerging strategies for combating in colorectal cancer treatment: Systematic review, improvements and future challenges.

Liu H, Yu Y, Dong A, Elsabahy M, Yang Y, Gao H Exploration (Beijing). 2024; 4(1):20230092.

PMID: 38854496 PMC: 10867388. DOI: 10.1002/EXP.20230092.


Comprehensive -Glycan Analysis by Porous Graphitized Carbon Nanoliquid Chromatography-Mass Spectrometry.

Zhang T, Wang W, Wuhrer M, de Haan N Anal Chem. 2024; 96(22):8942-8948.

PMID: 38758656 PMC: 11154684. DOI: 10.1021/acs.analchem.3c05826.


Unraveling the role of C1GALT1 in abnormal glycosylation and colorectal cancer progression.

Tian H, Yu J, Chu X, Guan Q, Liu J, Liu Y Front Oncol. 2024; 14:1389713.

PMID: 38699634 PMC: 11063370. DOI: 10.3389/fonc.2024.1389713.


Role of Post-Translational Modifications in Colorectal Cancer Metastasis.

Peng N, Liu J, Hai S, Liu Y, Zhao H, Liu W Cancers (Basel). 2024; 16(3).

PMID: 38339403 PMC: 10854713. DOI: 10.3390/cancers16030652.


References
1.
Oliveira-Ferrer L, Legler K, Milde-Langosch K . Role of protein glycosylation in cancer metastasis. Semin Cancer Biol. 2017; 44:141-152. DOI: 10.1016/j.semcancer.2017.03.002. View

2.
Chen D, Wang Z, Zeng Z, Wu W, Zhang D, Luo H . Identification of microRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression. Hepatology. 2014; 60(2):598-609. DOI: 10.1002/hep.27118. View

3.
Lenos K, Goos J, Vuist I, den Uil S, Delis-van Diemen P, Belt E . MGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patients. Oncotarget. 2015; 6(28):26278-90. PMC: 4694901. DOI: 10.18632/oncotarget.4495. View

4.
Bergstrom K, Liu X, Zhao Y, Gao N, Wu Q, Song K . Defective Intestinal Mucin-Type O-Glycosylation Causes Spontaneous Colitis-Associated Cancer in Mice. Gastroenterology. 2016; 151(1):152-164.e11. PMC: 5068133. DOI: 10.1053/j.gastro.2016.03.039. View

5.
Holst S, Wuhrer M, Rombouts Y . Glycosylation characteristics of colorectal cancer. Adv Cancer Res. 2015; 126:203-56. DOI: 10.1016/bs.acr.2014.11.004. View